{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=8", "query": { "intervention": "Torisel", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 647, "total_pages": 65, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T15:42:40.448Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07062965", "title": "A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PF-07248144", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2025-08-05", "completion_date": "2030-11-04", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-27T15:42:40.448Z", "location_count": 215, "location_summary": "Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07062965" }, { "nct_id": "NCT01231399", "title": "Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "microarray analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "OTHER", "GENETIC" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 6, "start_date": "2012-02", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-10-27T15:42:40.448Z", "location_count": 3, "location_summary": "Duarte, California • South Pasadena, California • Tampa, Florida", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231399" }, { "nct_id": "NCT06287944", "title": "225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Actinium Ac 225-DOTA-Daratumumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Indium In 111-DOTA-Daratumumab", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total Marrow and Lymphoid Irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2025-07-01", "completion_date": "2028-05-19", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-27T15:42:40.448Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06287944" }, { "nct_id": "NCT00985192", "title": "Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Translational Oncology Research International", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2009-09", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2020-08-05", "last_synced_at": "2026-10-27T15:42:40.448Z", "location_count": 18, "location_summary": "Alhambra, California • Bakersfield, California • Fullerton, California + 12 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00985192" }, { "nct_id": "NCT01184898", "title": "Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "AML" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2010-07", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-10-27T15:42:40.448Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01184898" }, { "nct_id": "NCT03253913", "title": "Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphangioleiomyomatosis" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Resveratrol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2018-03-31", "completion_date": "2022-10-15", "has_results": true, "last_update_posted_date": "2023-02-01", "last_synced_at": "2026-10-27T15:42:40.448Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03253913" }, { "nct_id": "NCT01332279", "title": "Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Tongue Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "polyacrylamide gel electrophoresis", "type": "GENETIC" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "external beam radiation therapy", "type": "RADIATION" }, { "name": "microarray analysis", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "GENETIC", "RADIATION" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2011-04", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-10-27T15:42:40.448Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01332279" }, { "nct_id": "NCT03018223", "title": "Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Acute Leukemia in Remission", "Chronic Myeloid Leukemia", "Primary Myelofibrosis", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndromes", "Hodgkin Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total body irradiation (TBI)", "type": "RADIATION" }, { "name": "Peripheral Blood Hematopoietic Cell Transplantation (HCT)", "type": "PROCEDURE" }, { "name": "Sirolimus (SIR)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Granulocyte-colony stimulating factor (G-CSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-01-31", "completion_date": "2021-03-18", "has_results": true, "last_update_posted_date": "2021-09-16", "last_synced_at": "2026-10-27T15:42:40.448Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03018223" }, { "nct_id": "NCT01188889", "title": "RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-09", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2015-05-15", "last_synced_at": "2026-10-27T15:42:40.448Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01188889" }, { "nct_id": "NCT00012142", "title": "CCI-779 in Treating Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": "2000-09", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-27T15:42:40.448Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00012142" } ] }